Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

A systematic review of randomized controlled trials (RCTs) found that weight-loss interventions were associated with improvements in some polycystic ovary syndrome (PCOS) symptoms, including ...

There are a handful of patients in DESTINY-Breast03 with active brain metastasis that were enrolled, and they did look and ...

The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...

Medically reviewed by Lindsay Cook, PharmD If you have HER2-positive breast cancer, your options for treatment will depend on ...

Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment ...

She focused on 2 FDA-approved antibody drug conjugates (ADCs): trastuzumab deruxtecan (T-DXd; Enhertu; Daiichi Sankyo/AstraZeneca) and sacituzumab govitecan (SG), which have both demonstrated ...

However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment with trastuzumab deruxtecan (T-Dxd), which includes a topoisomerase I inhibitor payload.

MSK developed a cancer drug that’s giving people with stage 4 breast cancer new hope. The drug, T-DXd, was approved in 2022. T-DXd is now being tested on other cancers and is changing the way doctors ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...